Acura Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACUR research report →
Price Chart
About the company
Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain.
- CEO
- Robert Jones
- IPO
- 1986
- Employees
- 9
- HQ
- Palatine, IL, US
Get TickerSpark's AI analysis on ACUR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.60K
- P/E
- -0.01
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -0.24
- Div Yield
- 0.00%
- Gross Margin
- 94.24%
- Op Margin
- -77.67%
- Net Margin
- -56.24%
- ROE
- 30.77%
- ROIC
- -295.38%
Latest fiscal year · YoY change
- Revenue
- $1.56M-56.2%
- Gross Profit
- $1.47M-58.7%
- Op Income
- $-1,214,000
- Net Income
- $-879,000+27.2%
- EPS
- $-0.02+50.0%
- OCF Growth
- -3.2%
- FCF Growth
- -3.2%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -54.49
- RSI (14)
- 40
- Avg Volume
- 640
No earnings-call transcripts are available for ACUR yet.
- Free Float
- 97.3%
- Shares Outstanding
- 66.00M
- Float Shares
- 64.20M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Fund Advisors | 10.52K | ▲ 2.16K |
| Blackrock Advisors LLC | 3.20K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 25 | THANGARAJ IMMANUEL | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACUR coverage
Recent articles, reports, and earnings notes.
No research on ACUR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACUR report →Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?
defenseworld.net · Nov 19
Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results
globenewswire.com · Aug 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.